Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 2/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.65 |
| ▸ | MEN1 | O00255 | 4/20 | 0.65 |
| ▸ | LMNA | P02545 | 3/20 | 0.65 |
| ▸ | MAPT | P10636 | 2/20 | 0.62 |
| ▸ | GAA | P10253 | 1/20 | 0.62 |
| ▸ | GFER | P55789 | 1/20 | 0.62 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.59 |
| ▸ | RAB9A | P51151 | 4/20 | 0.57 |
| ▸ | NPC1 | O15118 | 3/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | CASP3 | P42574 | 1/20 | 0.57 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.57 |
| ▸ | HPGD | P15428 | 2/20 | 0.56 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.56 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | GLA | P06280 | 2/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL62827 | 0.92 | PTPN1 (0.71) | NAMPTKMT2AMEN1LMNAMAPT | |
| SCHEMBL12460635 | 0.92 | PTPN1 (0.66) | NAMPTKMT2AMEN1LMNAMAPT | |
| SCHEMBL14618675 | 0.82 | NAMPT (0.69) | NAMPTKMT2AMEN1LMNAMAPT | |
| SCHEMBL7865123 | 0.80 | NAMPT (0.72) | NAMPTKMT2AMEN1LMNAMAPT | |
| SCHEMBL13135280 | 0.80 | NAMPT (0.72) | NAMPTKMT2AMEN1LMNAMAPT | |
| SCHEMBL23898941 | 0.80 | NAMPT (0.67) | NAMPTKMT2AMEN1LMNAMAPT | |
| SCHEMBL23899043 | 0.80 | NAMPT (0.67) | NAMPTKMT2AMEN1LMNAMAPT | |
| SCHEMBL9342656 | 0.80 | KMT2A (0.72) | NAMPTKMT2AMEN1LMNAMAPT | |
| SCHEMBL2719839 | 0.80 | NAMPT (0.67) | NAMPTKMT2AMEN1LMNAMAPT | |
| SCHEMBL14734057 | 0.80 | KMT2A (0.78) | NAMPTKMT2AMEN1LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 128 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120118411-A | Marine power cable | 西隆电缆有限公司 | 2025-06-10 | — | — | CN | claimed |
| CN-120118411-A | Marine power cable | 西隆电缆有限公司 | 2025-06-10 | — | — | CN | disclosed |
| CN-109666160-B | Dynamic polymer with hybrid cross-linked network | 厦门天策材料科技有限公司 | 2023-07-14 | — | — | CN | disclosed |
| US-20200399250-A1 | Pyrimidine Derivatives as Tropomyosin Receptor Kinase A (TRKA) Inhibitors | BIOMED X GMBH (DE) | 2020-12-24 | — | — | US | disclosed |
| EP-3672957-A1 | PYRIMIDINE DERIVATIVES AS TROPOMYOSIN RECEPTOR KINASE A (TRKA) INHIBITORS | BioMed X GmbH (DE) | 2020-07-01 | — | — | EP | disclosed |
| WO-2019101843-A1 | PYRIMIDINE DERIVATIVES AS TROPOMYOSIN RECEPTOR KINASE A (TRKA) INHIBITORS | BIOMED X GMBH (DE) | 2019-05-31 | — | — | WO | disclosed |
| CN-109666160-A | A kind of dynamic aggregation object with hybrid cross-linked network | 翁秋梅 | 2019-04-23 | — | — | CN | disclosed |
| US-9382229-B2 | Compounds and methods of use thereof for treating neurodegenerative disorders | THE JOHNS HOPKINS UNIVERSITY (US) | 2016-07-05 | — | — | US | disclosed |
| US-9382229-B2 | Compounds and methods of use thereof for treating neurodegenerative disorders | THE JOHNS HOPKINS UNIVERSITY (US) | 2016-07-05 | — | — | US | disclosed |
| US-9078902-B2 | Triazine derivatives and their therapeutical applications | NANTBIOSCIENCE, INC. (US) | 2015-07-14 | — | — | US | disclosed |
| WO-2007056221-A2 | AMINOPYRIMIDINES USEFUL AS KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-05-18 | — | — | WO | disclosed |
| EP-1778669-A2 | KINASE INHIBITORS | Takeda San Diego, Inc. (US) | 2007-05-02 | — | — | EP | disclosed |
| WO-2007022384-A2 | PYRAZINE KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-02-22 | — | — | WO | disclosed |
| WO-2007014250-A2 | ABL KINASE INHIBITION | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-02-01 | — | — | WO | disclosed |
| EP-1746093-A1 | Process for preparing substituted pyrimidines | Vertex Pharmaceuticals Incorporated (US) | 2007-01-24 | — | — | EP | disclosed |
| WO-2006055831-A2 | KINASE INHIBITORS | MIIKANA THERAPEUTICS, INC. (US) | 2006-05-26 | — | — | WO | disclosed |
| WO-2006044687-A2 | KINASE INHIBITORS | TAKEDA SAN DIEGO, INC. (US) | 2006-04-27 | — | — | WO | disclosed |
| US-20060084650-A1 | Kinase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-04-20 | — | — | US | disclosed |
| WO-2006023931-A2 | KINASE INHIBITORS | TAKEDA SAN DIEGO, INC. (US) | 2006-03-02 | — | — | WO | disclosed |
| US-20060041137-A1 | Kinase inhibitors | TAKEDA SAN DIEGO, INC. | 2006-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060084650-A1 | Kinase inhibitors | MAP3K20, MAP3K19, MAP3K1 | NAMPT 737/4885KMT2A 1184/4885MEN1 1423/4885 |
| US-20060041137-A1 | Kinase inhibitors | MAP3K19, MAP3K20, MAP3K1 | NAMPT 2174/4885KMT2A 897/4885MEN1 1654/4885 |
| US-20200399250-A1 | Pyrimidine Derivatives as Tropomyosin Receptor Kinase A (TRKA) Inhibitors | TPM3, NGF, TK1 | NAMPT 269/4885KMT2A 3621/4885MEN1 4855/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.